Sun Pharma acquires Novartis' oncology brand Odomzo
The Dollar Business Bureau Mumbai-based pharmaceutical company Sun Pharma has acquired a branded oncology product, Odomzo (sonidegib), from Novartis after making an upfront payment of $175 million (about Rs 1180 crore) and some additional milestone payments. The deal has been fixed between subsidiaries of both the companies and will be finalised after putting in place some anti-trust clearance and further closing conditions. Odomzo is a hedgehog pathway inhibitor which was approved by the US FDA in July 2015. It has been indicated for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. The prescription of these drugs is made by around ...
Glenmark gets tentative USFDA nod for Lacosamide tablets
The Dollar Business Bureau Mumbai-based drug maker Glenmark Pharmaceuticals Ltd. on Friday announced that it has received tentative approvals from the United States Food & Drug Administration (USFDA) to market its Lacosamide tablets, 50 mg, 100 mg, 150 mg and 200 mg. The generic version of this medicine is currently listed under Vimpat tablets, 50 mg, 100 mg, 150 mg and 200 mg of UCB— a multinational biopharmaceutical company headquartered in Brussels, Belgium. “Glenmark will market this product upon receiving final approval of its Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg ANDA. The patent listed in the Orange Book for Vimpat Tablets, 50 mg, 100 mg, 150 mg and 200 mg is scheduled to expire on March ...
